Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Sponsor
October 6 University
Study ID
NCT06142656
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Poly Cystic Ovary Syndrome

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Metformin Hydrochloride tablet — DRUG
    Metformin Hydrochloride 850 mg oral tablet
  • Vildagliptin 50 MG — DRUG
    Vildagliptin 50 MG oral tablets

Study Details

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

Key Dates

Start date
Nov 25, 2023
Status verified
Jul 2025
Primary completion
Dec 1, 2025
Completion
Feb 1, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Metformin
  • Active Comparator: Vildagliptin

Primary Outcome Measure

Concentration of luteinizing hormone (LH) [ Time Frame: at baseline and after 3 months ]

Central Contacts